On November 16, 2020 PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, reported that the European Patent Office (EPO) has informed the company that a new European patent has been granted (Press release, PCI Biotech, NOV 16, 2020, View Source [SID1234585149]). The European patent covers the intended use of fimaChem in combination with gemcitabine for the treatment of cholangiocarcinoma (bile duct cancer).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Per Walday, CEO, comments: We are very happy to see this patent granted in Europe, which provides an extended protection of the intended use of fimaChem lasting several years beyond the potential market exclusivity offered by the orphan designation. Our full focus is now on the successful delivery of the global pivotal RELEASE study.

Today’s announced European patent secure protection until 2037. The patent application is still pending in US and key Asian markets.